{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:21:27Z","timestamp":1767651687793},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.schres.2003.09.016","type":"journal-article","created":{"date-parts":[[2003,12,4]],"date-time":"2003-12-04T13:59:39Z","timestamp":1070546379000},"page":"57-62","source":"Crossref","is-referenced-by-count":38,"title":["Weight decline in patients switching from olanzapine to quetiapine"],"prefix":"10.1016","volume":"70","author":[{"given":"Sanjay","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash S","family":"Masand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubdeep","family":"Virk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradford L","family":"Frank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Lockwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2003.09.016_BIB1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00023210-199809020-00005","article-title":"Bodyweight gain-induced by psychotropic drugs","volume":"9","author":"Ackerman","year":"1998","journal-title":"CNS Drugs"},{"issue":"Suppl. 7","key":"10.1016\/j.schres.2003.09.016_BIB2","first-page":"22","article-title":"Antipsychotic-induced weight gain: a review of the literature","volume":"62","author":"Allison","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2003.09.016_BIB3","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2003.09.016_BIB4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-200209000-00001","article-title":"1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg\/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study","volume":"17","author":"Arato","year":"2002","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2003.09.016_BIB13","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.schres.2003.09.016_BIB6","doi-asserted-by":"crossref","DOI":"10.1016\/S0924-9338(02)80462-X","article-title":"Patient attitude after switch to ziprasidone from other antipsychotics","author":"Awad","year":"2002"},{"key":"10.1016\/j.schres.2003.09.016_BIB7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4088\/JCP.v62n0404","article-title":"Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone","volume":"62","author":"Basson","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2003.09.016_BIB8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/13651500050517849","article-title":"The long-term effect of quetiapine monotherapy on weight in patients with schizophrenia","volume":"4","author":"Brecher","year":"2000","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.schres.2003.09.016_BIB9","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1056\/NEJM199910073411501","article-title":"Body-mass index and mortality in a prospective cohort of U.S. adults","volume":"341","author":"Calle","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2003.09.016_BIB11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1592\/phco.21.7.717.34575","article-title":"Ziprasidone, a new atypical antipsychotic drug","volume":"21","author":"Carnahan","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.schres.2003.09.016_BIB10","first-page":"S187","article-title":"Switching to aripiprazole monotherapy","volume":"5","author":"Casey","year":"2002","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2003.09.016_BIB12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00004714-200206000-00003","article-title":"Antipsychotic-induced weight gain and therapeutic response: a differential association","volume":"22","author":"Czobor","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"issue":"Suppl. 21","key":"10.1016\/j.schres.2003.09.016_BIB14","first-page":"20","article-title":"Weight gain associated with antipsychotic drugs","volume":"60","author":"Ganguli","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2003.09.016_BIB16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/10401239809148817","article-title":"Olanzapine-induced weight gain","volume":"10","author":"Gupta","year":"1998","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2003.09.016_BIB17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00004714-199906000-00014","article-title":"Olanzapine: weight gain and therapeutic efficacy","volume":"19","author":"Gupta","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2003.09.016_BIB19","doi-asserted-by":"crossref","DOI":"10.1016\/S0924-977X(02)80411-4","article-title":"Meta-analysis of weight effects with aripiprazole","author":"Jody","year":"2002"},{"key":"10.1016\/j.schres.2003.09.016_BIB18","article-title":"Weight changes in patients treated with quetiapine","author":"Jones","year":"2000"},{"key":"10.1016\/j.schres.2003.09.016_BIB20","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1517\/14656566.1.4.783","article-title":"Review of quetiapine and its clinical applications in schizophrenia","volume":"1","author":"Kasper","year":"2000","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.schres.2003.09.016_BIB21","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1517\/14656566.2.6.1033","article-title":"Ziprasidone: a new atypical antipsychotic","volume":"2","author":"Keck","year":"2001","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.schres.2003.09.016_BIB23","first-page":"4","article-title":"Weight gain associated with atypical antipsychotics","volume":"11","author":"Masand","year":"1998","journal-title":"J. Psychotic Disord."},{"key":"10.1016\/j.schres.2003.09.016_BIB24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1517\/14656566.1.3.377","article-title":"Weight gain associated with psychotropic drugs","volume":"1","author":"Masand","year":"2000","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.schres.2003.09.016_BIB26","first-page":"299","article-title":"Long-term adverse effects of atypical antipsychotics","volume":"6","author":"Masand","year":"2000","journal-title":"Psychiatr. Prakt."},{"key":"10.1016\/j.schres.2003.09.016_BIB22","author":"McIntyre","year":"2001"},{"key":"10.1016\/j.schres.2003.09.016_BIB27","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1001\/jama.282.16.1523","article-title":"The disease burden associated with overweight and obesity","volume":"282","author":"Must","year":"1999","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.schres.2003.09.016_BIB28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0306-4530(02)00114-2","article-title":"A review of the effect of atypical antipsychotics on weight","volume":"28","author":"Nasrallah","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2003.09.016_BIB30","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/archinte.160.7.898","article-title":"Overweight, obesity, and health risk","volume":"160","author":"National Task Force on the Prevention and Treatment of Obesity","year":"2000","journal-title":"Arch. Intern. Med."},{"issue":"Suppl 10","key":"10.1016\/j.schres.2003.09.016_BIB29","first-page":"45","article-title":"Dosing the antipsychotic medication olanzapine","volume":"58","author":"Nemeroff","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2003.09.016_BIB15","unstructured":"Pfizer, 2002. Geodon. Full prescribing information."},{"key":"10.1016\/j.schres.2003.09.016_BIB31","volume":"vol. 24, Suppl. 1","author":"Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","year":"2001"},{"key":"10.1016\/j.schres.2003.09.016_BIB32","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/S0140-6736(02)08913-4","article-title":"Association of antipsychotic drug induced weight gain with a 5HT2C receptor gene polymorphism","volume":"359","author":"Reynolds","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2003.09.016_BIB33","author":"Simpson","year":"2000"},{"key":"10.1016\/j.schres.2003.09.016_BIB34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0149-2918(02)85003-2","article-title":"Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia","volume":"24","author":"Stimmel","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.schres.2003.09.016_BIB35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0140-6736(00)03643-6","article-title":"Brain dopamine and obesity","volume":"357","author":"Wang","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2003.09.016_BIB36","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00004714-199908000-00006","article-title":"Weight gain: side effect of atypical neuroleptics?","volume":"19","author":"Wetterling","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2003.09.016_BIB37","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4088\/JCP.v60n0602","article-title":"Novel antipsychotics: comparison of weight gain liabilities","volume":"60","author":"Wirshing","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2003.09.016_BIB38","first-page":"238","article-title":"Atypical antipsychotic agents: a critical review","volume":"57","author":"Worrel","year":"2000","journal-title":"Am. J. Health-Syst."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996403002913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996403002913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T15:41:50Z","timestamp":1682610110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996403002913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0920996403002913"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2003.09.016","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}